Bernd Brust will transition out of his position as president of Life Technologies' commercial operations and will take on the role of president of molecular medicine at the company, according to a filing yesterday with the US Securities and Exchange Commission.
Brust will be replaced as president of commercial operations at the start of 2011 by Nicolas Barthelemy, who has been leading Life Technologies' cell systems division.
Life Technologies said that its molecular medicine business unit was formed to enable the development of new strategies related to transitioning next-generation sequencing activities into clinical uses.
Caris Life Sciences announced last month several recent additions and appointments to its senior scientific staff at its facilities in Lausanne, Switzerland, and Phoenix, Ariz.
Andy Tasinato was named director of research at the company's new R&D lab in Lausanne. Previously he was head of research at the University Hospital Lausanne and Bern. He will be overseeing Elodie Ristorcelli, who received her doctorate in biochemistry at the Faculty of Medicine in Marseille; and Gherici Hassaine, previously head of BioXtal's R&D laboratory.
Dan Holterman joined the company's Phoenix facility as a senior research scientist along with scientists Wang-Juh Chen, Jorge Schettini, and Tassilo Hornung.